| 87.08 -3.45 (-3.81%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 131.06  |
1-year : | 150.13 |
| Resists | First : | 112.21 |
Second : | 128.53 |
| Pivot price | 96.57 |
|||
| Supports | First : | 85.79 |
Second : | 71.38 |
| MAs | MA(5) : | 91.74 |
MA(20) : | 99.35 |
| MA(100) : | 98.1 |
MA(250) : | 87.91 |
|
| MACD | MACD : | -4.5 |
Signal : | -3.2 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 10.1 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 155.28 | Low : | 28.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INBX ] has closed below the lower bollinger band by 1.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 25.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 92.63 - 93.16 | 93.16 - 93.73 |
| Low: | 84.39 - 84.95 | 84.95 - 85.55 |
| Close: | 86.03 - 87 | 87 - 88.05 |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Tue, 13 Oct 2026
Inhibrx Announces Participation in Upcoming Scientific Conferences - PR Newswire
Tue, 29 Sep 2026
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating - Yahoo Finance
Mon, 28 Sep 2026
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares. - Stock Titan
Thu, 24 Sep 2026
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? - Yahoo Finance
Wed, 23 Sep 2026
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Thu, 13 Aug 2026
Inhibrx Reports Second Quarter 2026 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 8.59e+006 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 3,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.256e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 202.51 |
| EBITDA (p.s.) | -2.69634e+007 |
| Qtrly Earnings Growth | -8.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.42 |
| Price to Cash Flow | -92.41 |
| Dividend | 0 |
| Forward Dividend | 3.43e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|